66108-85-8Relevant articles and documents
Reactions of 1-methylbenzimidazole derivatives with m-chloroperoxybenzoic acid
Kaiya, Toyo,Aoyama, Shinsuke,Kohda, Kohfuku
, p. 625 - 630 (1998)
Oxidation of seven 1-methylbenzimidazole (MBI) derivatives (with pKa's ranging from 1.6 to 6.0) was carried out with m-chloroperoxybenzoic acid and structures of the products formed were identified. (Condensed benzene moiety-hydroxylated)-2-(m-chlorobenzyloxy)-MBIs and 2-oxo-MBIs were obtained from MBIs with pKa's of more than 5.6 and about 3.3, respectively.
Achieving in Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders
Bellenie, Benjamin R.,Cheung, Kwai-Ming J.,Varela, Ana,Pierrat, Olivier A.,Collie, Gavin W.,Box, Gary M.,Bright, Michael D.,Gowan, Sharon,Hayes, Angela,Rodrigues, Matthew J.,Shetty, Kartika N.,Carter, Michael,Davis, Owen A.,Henley, Alan T.,Innocenti, Paolo,Johnson, Louise D.,Liu, Manjuan,De Klerk, Selby,Le Bihan, Yann-Va?,Lloyd, Matthew G.,McAndrew, P. Craig,Shehu, Erald,Talbot, Rachel,Woodward, Hannah L.,Burke, Rosemary,Kirkin, Vladimir,Van Montfort, Rob L. M.,Raynaud, Florence I.,Rossanese, Olivia W.,Hoelder, Swen
, p. 4047 - 4068 (2020/04/20)
Deregulation of the transcriptional repressor BCL6 enables tumorigenesis of germinal center B-cells, and hence BCL6 has been proposed as a therapeutic target for the treatment of diffuse large B-cell lymphoma (DLBCL). Herein we report the discovery of a series of benzimidazolone inhibitors of the protein-protein interaction between BCL6 and its co-repressors. A subset of these inhibitors were found to cause rapid degradation of BCL6, and optimization of pharmacokinetic properties led to the discovery of 5-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (CCT369260), which reduces BCL6 levels in a lymphoma xenograft mouse model following oral dosing.
Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
-
, (2008/06/13)
The present invention relates to 5-membered heterocyclic condensed benzoderivatives of formula wherein Ra to Rc, A, X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable properties. The compounds of the above formula I wherein Rc denotes a cyano group are valuable intermediates for preparing the other compounds of formula I, and the compounds of the above formula I wherein Rc denotes one of the following amidino groups and the tautomers and stereoisomers thereof have valuable pharmacological properties, particularly an antithrombotic activity.